Evaluation of the Post-COVID-19 Functional Status (PCFS) Scale in a cohort of patients recovering from hypoxemic SARS-CoV-2 pneumonia

Naïla Benkalfate, Emmanuel Eschapasse, Thomas Georges, Camille Leblanc, Stephanie Dirou, Lise Melscoet, Anne-Laure Chéné, Delphine Horeau-Langlard, Charlotte Bry, Arnaud Chambellan, Aymeric Nicolas, Defrance Claire, Renan Liberge, Matilde Karakachoff, Jean-Benoit Hardouin, François-Xavier Blanc, Patricia Lemarchand

ABSTRACT

Introduction COVID-19 sequelae are numerous and multisystemic, and how to evaluate those symptomatic patients is a timely issue. Klok et al proposed the Post-COVID-19 Functional Status (PCFS) Scale as an easy tool to evaluate limitations related to persistent symptoms. Our aim was to analyse PCFS Scale ability to detect functional limitations and its correlation with quality of life in a cohort of patients, 2–9 months after hospitalisation for COVID-19 hypoxemic pneumonia.

Methods PCFS Scale was evaluated in 121 patients together with quality of life and dyspnoea questionnaires, pulmonary function tests and CT scans.

Results We observed a high correlation with multiple questionnaires (Short Form-36, Hospital Anxiety and Depression Scale, modified Medical Research Council, end Borg Six-Minute Walk Test), making the PCFS Scale a quick and global tool to evaluate functional limitations related to various persistent symptoms following COVID-19 pneumonia.

Discussion The PCFS Scale seems to be a suitable instrument to screen for patients who will require careful follow-up after COVID-19 hypoxemic pneumonia even in the absence of pulmonary sequelae.

INTRODUCTION

The consequences that result from the COVID-19 pandemic are numerous. A few studies have already highlighted both high frequency and heterogeneity of post COVID-19 symptoms. Indeed, many symptoms have been described up to 6 months after the acute phase of COVID-19, including asthenia, muscle weakness, anxiety, depression, sleep disorder and respiratory manifestations. If most of these symptoms are reversible, some last over time and significantly alter daily life. If not taken seriously, they could evolve towards a chronic disease with major public health and economic consequences.

Because of the vast number of patients and range of clinical symptoms, a simple and reproducible questionnaire is crucial to identify patients with functional limitations. A year ago, the ‘Post-COVID-19 Functional Status (PCFS) Scale’ was proposed by Klok et al as an easy tool to identify people with incomplete recovery. It focuses on daily-life limitations connected to persistent symptoms. Machado et al already described a relationship between the PCFS Scale and two scores that assess health-related quality of life (EuroQoL-5D-5L), daily life and work impairment. However, it was based on a population of symptomatic patients who volunteered, of
whom only 5% had been hospitalised during the acute phase of COVID-19. In the present study, we assessed the PCFS Scale in a cohort of patients recovering from hypoxemic COVID-19 pneumonia and analysed its ability to detect functional limitations related to remaining symptoms and its correlation with quality of life using Short Form-36 (SF-36) and mental health and dyspnoea questionnaires.

**METHODS**

**Study design and inclusion criteria**

This observational, monocentric prospective study was conducted at Nantes University Hospital, France, between June 2020 and March 2021. Patients aged between 18 and 75 years admitted with hypoxemic COVID-19 pneumonia, confirmed by reverse transcription-PCR or chest CT scan, were routinely proposed a follow-up with a pulmonologist after discharge.

**Construct validity and study objectives**

The PCFS was translated into French by the authors (online supplemental figure 1) and then back-translated into English by a native English speaker. Multiple self-administered questionnaires were fulfilled: French translation of the PCFS Scale, the modified Medical Research Council (mMRC) Scale, the Multidimensional Dyspnea Profile (MDP), the SF-36 questionnaire and the Hospital Anxiety and Depression Scale (HAD A and D). Patients also underwent physical examination and pulmonary functional tests. When possible, a chest CT scan and a Six-Minute Walk Test (6MWT) were performed (see online supplemental methods).

The main study aim was to evaluate the validity of the French translation of the PCFS Scale to detect limitations secondary to the wide spectrum of symptoms remaining after COVID-19 pneumonia. To achieve that, we analysed its correlation with questionnaires exploring dyspnoea, quality of life and psychiatric state. The secondary aim was to verify whether the PCFS Scale could be suited to

---

**Table 1** Patient characteristics according to their PCFS Scale Score

<table>
<thead>
<tr>
<th>PCFS n (%)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3–4*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years, mean±SD</td>
<td>57±12</td>
<td>57±11</td>
<td>59±11</td>
<td>59±13</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>12 (33)</td>
<td>13 (37)</td>
<td>13 (37)</td>
<td>7 (47)</td>
</tr>
<tr>
<td>Body mass index, kg/m², n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18–24</td>
<td>6 (17)</td>
<td>11 (31)</td>
<td>8 (23)</td>
<td>3 (20)</td>
</tr>
<tr>
<td>25–30</td>
<td>19 (53)</td>
<td>15 (43)</td>
<td>10 (29)</td>
<td>6 (40)</td>
</tr>
<tr>
<td>&gt;30</td>
<td>11 (31)</td>
<td>9 (26)</td>
<td>17 (49)</td>
<td>6 (40)</td>
</tr>
<tr>
<td>Current or former smokers, n (%)</td>
<td>20 (56)</td>
<td>19 (54)</td>
<td>16 (46)</td>
<td>7 (47)</td>
</tr>
<tr>
<td>Comorbidities†, n (%)</td>
<td>20 (56)</td>
<td>20 (57)</td>
<td>16 (46)</td>
<td>7 (47)</td>
</tr>
<tr>
<td>Total duration of hospitalisation, days, median (IQR)</td>
<td>11 (7; 15)</td>
<td>9 (6; 16)</td>
<td>13 (7; 29)</td>
<td>14 (9; 25)</td>
</tr>
<tr>
<td>ICU stay, n (%)</td>
<td>14 (39)</td>
<td>17 (49)</td>
<td>16 (46)</td>
<td>10 (67)</td>
</tr>
<tr>
<td>Duration of ICU stay, days, median (IQR)</td>
<td>10 (5; 19)</td>
<td>9 (6; 14)</td>
<td>18 (10; 29)</td>
<td>5 (2; 17)</td>
</tr>
<tr>
<td>Mechanical ventilation, n (%)</td>
<td>9 (25)</td>
<td>9 (26)</td>
<td>11 (31)</td>
<td>4 (27)</td>
</tr>
<tr>
<td>Mechanical ventilation duration, days, median (IQR)</td>
<td>13 (6; 15)</td>
<td>9 (7; 20)</td>
<td>18 (8; 24)</td>
<td>11 (7; 19)</td>
</tr>
<tr>
<td>Total duration of oxygen therapy, days, median (IQR)</td>
<td>9 (6; 19)</td>
<td>9 (4; 16)</td>
<td>12 (6; 25)</td>
<td>13 (7; 21)</td>
</tr>
<tr>
<td>Corticosteroids, n (%)</td>
<td>19 (53)</td>
<td>21 (60)</td>
<td>17 (49)</td>
<td>9 (60)</td>
</tr>
<tr>
<td>Rehabilitation‡, n (%)</td>
<td>8 (22)</td>
<td>8 (23)</td>
<td>11 (31)</td>
<td>6 (40)</td>
</tr>
<tr>
<td>Weekly activity duration before COVID-19, min, median (IQR)</td>
<td>60 (0; 120)</td>
<td>60 (0; 180)</td>
<td>60 (0; 120)</td>
<td>60 (0; 180)</td>
</tr>
</tbody>
</table>

The PCFS Scale assesses patient-relevant functional limitations: grade 0 reflects the absence of any functional limitation. Upward of grade 1, symptoms, pain or anxiety are present to an increasing degree. This has no effect on activities for patients in grade 1, whereas a lower intensity of the activities is required for those in grade 2. Grade 3 accounts for inability to perform certain activities, forcing patients to structurally modify these. Finally, grade 4 is reserved for those patients with severe functional limitations requiring assistance with activities of daily living.6

*Patients in categories # 3 (n=13) and 4 (n=2) were merged.
†History of chronic respiratory disease, chronic cardiac disease, arterial hypertension, diabetes, chronic kidney disease, immunodepression, psychiatric disease and thromboembolic disease.
‡Includes patients who underwent respiratory rehabilitation as well as standard recovery centres following discharge.
ICU, intensive care unit; PCFS, Post-COVID-19 Functional Status.
Overall, 106 patients (88%) had a PCFS Scale Score at admission for severe COVID-19 pneumonia (online supplemental figure 2), only 44 patients (36.4%) had a restored PCFS Scale Score at discharge. Determining a PCFS Scale threshold could be best suited to explore the physical impact of COVID-19. Indeed, SF-36 is a lengthy questionnaire that can hardly be used in everyday practice. The strong correlation with the physical composite score suggests that the PCFS Scale could be better suited to explore the physical impact of COVID-19.

**RESULTS**

A total of 121 patients were enrolled in the study. At a median time of 125 days (59–284) after hospital admission for severe COVID-19 pneumonia (online supplemental figure 2), only 44 patients (36.4%) had a restored pre-COVID-19 condition (online supplemental table 1). Overall, 106 patients (88%) had a PCFS Scale Score at admission for severe COVID-19 pneumonia (online supplemental figure 2), only 44 patients (36.4%) had a restored PCFS Scale Score at discharge. Determining a PCFS Scale threshold could be best suited to explore the physical impact of COVID-19. Indeed, SF-36 is a lengthy questionnaire that can hardly be used in everyday practice. The strong correlation with the physical composite score suggests that the PCFS Scale could be better suited to explore the physical impact of COVID-19.

**DISCUSSION**

In patients having suffered from severe COVID-19 pneumonia, our data showed that the PCFS Scale correlated with SF-36, dyspnoea and mental health questionnaires, making it a global and easy tool to detect functional limitations related to the multiple aspects of post-COVID-19. Indeed, SF-36 is a lengthy questionnaire that can hardly be used in everyday practice. The strong correlation with the physical composite score suggests that the PCFS Scale could be better suited to explore the physical impact of COVID-19.

**Table 2** Comparison of the PCFS Scale and 6MWT end Borg rating according to the type of sequelae

<table>
<thead>
<tr>
<th>Type of sequelae</th>
<th>No pulmonary sequelae, n=27</th>
<th>Isolated dyspnoea, n=41</th>
<th>Pulmonary sequelae, n=53</th>
<th>P value Between three groups*</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCFS Scale (mean±SD)</td>
<td>0.6±0.8</td>
<td>1.7±1</td>
<td>1.3±1.1</td>
<td>0.001</td>
</tr>
<tr>
<td>6MWT end Borg rating (mean±SD)</td>
<td>2.6±1.2</td>
<td>5.2±2.3</td>
<td>3.4±2.6</td>
<td></td>
</tr>
</tbody>
</table>

Isolated dyspnoea: patients who described remaining dyspnoea with no chest CT scan or TLco abnormalities. Pulmonary sequelae: patients who had at least a chest CT scan abnormality or TLco impairment, with or without associated dyspnoea (see online supplemental table 3).

*There was a significant difference between the PCFS Scale in the three groups. PCFS Scale and 6MWT end Borg rating results were then compared according to the type of described sequelae. Significant differences were observed between each group (p<0.05), except for the mean 6MWT end Borg rating in the no pulmonary sequelae and the pulmonary sequelae groups.

6MWT, Six-Minute Walk Test; PCFS, Post-COVID-19 Functional Status; TLco, carbon monoxide transfer factor.
that coincides with patients’ acceptable state could be interesting to target patients requiring careful prolonged medical follow-up after COVID-19.

In our study, we showed acceptable validity of the PCFS Scale according to the COSMIN (Consensus-based Standards for the selection of health Measurement Instrum ents) group standards by comparing it with other scales. We did not test ‘responsiveness’ to analyse the PCFS Scale ability to vary with treatment, for instance, physiotherapy. However, we retrospectively analysed the PCFS status before COVID-19 and 85% patients had a PCFS Scale of 0 at that time (data not shown).

In conclusion, the PCFS Scale correlated with quality of life, dyspnoea and mental health. The growing population of patients recovering from COVID-19 with persistent and disabling symptoms calls for specific rehabilitation programmes. The PCFS Scale may be a suitable instrument to search for functional limitations related to the wide range of symptoms following COVID-19 pneumonia. Importantly, these patients with functional limitations, but for some of them without pulmonary sequelae, will require careful follow-up, including deconditioning identification and treatment.

Author affiliations
1Nantes University, CHU Nantes, Department of Respiratory Medicine, l’institut du thorax, F-44000 Nantes, Pays de la Loire, France
2Nantes University, CHU Nantes, Department of Physiology, l’Institut du thorax, Laboratoire MIP, F-44000 Nantes, France
3Nantes University, CHU Nantes, Department of Radiology, F-44000 Nantes, France
4Nantes University, CHU Nantes, INSERM, Clinique des données, CIC 1413, F-44000 Nantes, France
5Nantes Université, Univ Tours, CHU Nantes, INSERM, MethodS in Patients-centered outcomes and H.Ealth Research, SPHERE, F-44000 Nantes, France
6Nantes University, CHU Nantes, CNRS, INSERM, l’institut du thorax, F-44000 Nantes, France

Contributors NB, EE and PL contributed to the study design, patient enrolment, data analysis and writing of the report. MK and J-BH contributed to the study design and data analysis. TG, CL, DH-L, LM, A-LC, SD, CB, AC and F-XB contributed to patient enrolment and follow-up. AN, DC and RL contributed to chest CT scan acquisition and analysis. PL was the author responsible for the overall content as the guarantor.

Funding This work was supported by the Institut de Recherche en Santé Respiratoire des Pays de la Loire. The authors thank the cluster LUNG innovAtion (LUNG O2) for logistic support.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and was approved by Nantes Teaching Hospital Ethics Committee (GNEDS). Written consent was obtained for each patient enrolled in the study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The data are de-identified participant data, they are available from MK and data reuse will be allowed limited to academic research and to non-commercial use only, after evaluation of research project.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Naila Benkalfate http://orcid.org/0000-0003-0841-6732
Emmanuel Eschapasse http://orcid.org/0000-0001-6900-6783
Thomas Georges http://orcid.org/0000-0002-4149-2967
Camille Leblanc http://orcid.org/0000-0003-0806-3770
Stephanie Diur http://orcid.org/0000-0001-4293-1075
Lise Melsoet http://orcid.org/0000-0001-6327-5835
Anne-Laure Chéné http://orcid.org/0000-0002-6916-7998
Delphine Horeau-Langlard http://orcid.org/0000-0002-2694-7660
Charlotte Bly http://orcid.org/0000-0002-7782-8707
Aymeric Nicolas http://orcid.org/0000-0003-4853-9582
Defrance Claire http://orcid.org/0000-0001-3768-0632
Renan Liberge http://orcid.org/0000-0001-7445-3125
Matilde Karakachoff http://orcid.org/0000-0003-4318-9141
Jean-Benoit Hardoun http://orcid.org/0000-0001-8664-623X
François-Xavier Blanc http://orcid.org/0000-0001-7644-2188
Patricia Lemarchand http://orcid.org/0000-0002-5330-2008

REFERENCES